Biohit Oyj

BIOBV

FI0009005482

Office Equipment

Market Closed - Nasdaq Helsinki Other stock markets 17:00:00 28/06/2024 BST			5-day change	1st Jan Change
2.02 ^EUR	0.00%		+1.00%	+7.16%

06-14	Finland's Biohit Names Chief Technology Officer	MT
04-15	Faron Pharmaceuticals reappoints former finance chief on interim basis	AN

Biohit Oyj Provides Earnings Guidance for the Full Year of 2019

August 14, 2019 at 07:30 am

Biohit Oyj provided earnings guidance for the full year of 2019. For the year, the company expects its 2019 net sales growing comparing 2018 (previous year EUR 9.9 million) but not above EUR 11 million.

Latest news about Biohit Oyj

Finland's Biohit Names Chief Technology Officer	06-14	MT
Faron Pharmaceuticals reappoints former finance chief on interim basis	04-15	AN
Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	02-14	CI
Biohit Names New Chief Commercial Officer	11-22	MT
Biohit Oyj Provides Earnings Guidance for the Period from 2024 to 2028	11-22	CI
Biohit Oyj Announces Changes in the Management Group	11-22	CI
Biohit Revises Earnings Guidance for 2023	09/08/23	CI
Biohit Oyj Reports Earnings Results for the Half Year Ended June 30, 2023	09/08/23	CI
Biohit Oyj Elects Vesa Silaskivi as Chairman of the Board of Directors	15/06/23	CI
Biohit Oyj Approves Election of Vesa Silaskivi as Members of Board of Directors	14/06/23	CI
Biohit Oyj Provides Earnings Guidance for the Year 2023	15/02/23	CI
Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2022	15/02/23	CI
Biohit Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	15/02/23	CI
Biohit Oyj Announces Executive Changes	15/12/22	CI
Biohit Appoints New CFO	06/09/22	MT
Biohit Oyj Appoints Jussi Sorvo as Chief Financial Officer, Effective on September 7, 2022	06/09/22	CI
Biohit Oyj Appoints Jussi Sorvo as Member of the Management, Effective on September 7, 2022	06/09/22	CI
Finnish Biotech Biohit Appoints CFO as CEO	02/09/22	MT
Biohit Oyj Announces Executive Changes	02/09/22	CI
Biohit Oyj Reports Earnings Results for the Half Year Ended June 30, 2022	10/08/22	CI
Biohit Oyj Revises Earnings Guidance for the Year 2022	03/08/22	CI
Biohit Oyj Appoints Lea Paloheimo as the Chairman of the Board of Directors	16/06/22	CI
Biohit Oyj Elects Kalle Härkönen as Board of Director	15/06/22	CI
Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2021	16/02/22	CI
Biohit Oyj Provides Earnings Guidance for the Year 2022	16/02/22	CI

Chart Biohit Oyj

Duration

Period

More charts

Company Profile

Biohit Oyj is a Finland-based company engaged in the development, manufacture and marketing of diagnostic tests and analysis systems. The Company operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. It provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Companyâs products are used in hospitals, healthcare centers and research institutions. It operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.

Sector

Office Equipment

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Biohit Oyj

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.02 EUR

Average target price

2.4 EUR

Spread / Average Target

+18.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Scientific & Precision Equipment

	1st Jan change	Capi.
BIOHIT OYJ	+7.16%	32.81M
TECAN GROUP AG	-12.41%	4.33B
OLINK HOLDING AB	+1.31%	3.15B
JEOL LTD.	+17.42%	2.22B
ECKERT & ZIEGLER SE	+11.04%	1.07B
PARK SYSTEMS CORP.	+7.78%	936M
NINGBO YONGXIN OPTICS CO.,LTD	-39.11%	928M
MLOPTIC CORP.	-57.14%	684M
PHENIX OPTICAL COMPANY LIMITED	-28.72%	629M
FOCUSED PHOTONICS (HANGZHOU), INC.	-36.34%	614M

Scientific & Precision Equipment

Biohit Oyj

Equities

BIOBV

FI0009005482

Office Equipment

Biohit Oyj Provides Earnings Guidance for the Full Year of 2019

EPS Revisions